Skip to main content
Premium Trial:

Request an Annual Quote

Dicerna Files for $69M IPO


Dicerna Pharmaceuticals disclosed in a regulatory filing this week that it is planning to raise up to $69 million through an initial public offering of its stock on the Nasdaq.

The number of shares to be offered, as well as the offering price, have yet to be determined. In August, the company raised $60 million in a private Series C round.

In a filing with the US Securities and Exchange Commission, Dicerna said that the proceeds from the IPO would be used to advance its pipeline of drugs based on its Dicer-substrate RNAi technology.

The first, called DCR-PH1, is being developed for primary hyperoxaluria 1, a rare inherited disorder characterized by the overproduction of oxalate in the kidneys, which results in the development of stones. Dicerna said it expects to begin clinical trials of this compound in 2015.

More advanced is the company's hepatocellular carcinoma drug DCR-M1711, which is expected to enter human testing in the first half of this year.

The company is also developing a variety of drugs for rare, inherited diseases of the liver, with clinical testing potentially beginning in 2015.

Dicerna also provided a snapshot of its financial performance, citing a 2012 net loss of $11.6 million on research and development expenses of $8 million, and nearly $55 million in cash and cash equivalents as of Sept. 30, 2013.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.